∂Board of Directors
Dr. Peter Burckhardt, EVA Basel, Investor Representative
Peter Burckhardt is President of the Board of „EVA – the Basel life sciences start-up agency“ since 2016 and before that was the CEO. He is member of the board in several of EVA’s portfolio companies. Since 2009, Peter Burckhardt is president of the BioBAC.
Peter Burckhardt joined Ciba-Geigy in 1984 where he started his career as a research chemist in Pharma Research. Later he held various management positions in Ciba-Geigy / Novartis. From 1996 – 1999 he was CEO of Novartis Animal Health Germany.
Peter Burckhardt has an education as a chemist and achieved his PhD at the University of Basel.
Dr. Christoph Esslinger, CSO, Board Member
Christoph Esslinger is the CSO and scientific founder of Memo Therapeutics AG and a pioneer of the discovery of therapeutic antibody candidates directly from human donors for immunotherapy of Alzheimer’s Disease and cancer. Prior to founding MEMO Therapeutics he held senior positions at CT Atlantic AG, Neurimmune AG and in academia.
Christoph Esslinger holds a diploma in Technical Biology from University of Stuttgart and a PhD in Molecular Immunology from the Ludwig Institute for Cancer Research, Lausanne Branch and University of Lausanne.
Dr. Dragan Gabulovski, Business Development & Strategy, Board Member
Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH).
Dr. Michael Sidler, Redalpine, Investor Representative
Partner at Redalpine. PhD in Life Sciences, Consultant at Boston Consulting Group, business developer at Prionics, M&A, investor, co-founder of Redalpine, CTI start-up coach.
Dr. Urs Spitz, Board Member
CEO & President Biosynth Group since 2004, Senior Manager Mettler Toledo, Strategy Consultant at Bain & Co.
Education: Research Fellow at MIT, Ph. D. in organic Chemistry The University of Chicago, MSc in organic Chemistry and IT University of Zürich.